Ravindra Majeti, Ph.D. - Publications

Affiliations: 
University of California, San Francisco, San Francisco, CA 
Area:
Signal transduction in lymphocytes

80 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, ... ... Majeti R, et al. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1802018. PMID 30811285 DOI: 10.1200/JCO.18.02018  0.56
2019 Benard B, Gentles AJ, Köhnke T, Majeti R, Thomas D. Data mining for mutation-specific targets in acute myeloid leukemia. Leukemia. PMID 30728456 DOI: 10.1038/s41375-019-0387-y  0.32
2019 Chao MP, Majeti R. Induced pluripotent stem cell modeling of malignant hematopoiesis. Experimental Hematology. PMID 30659850 DOI: 10.1016/j.exphem.2019.01.002  0.56
2018 Tvorogov D, Thomas D, Liau NPD, Dottore M, Barry EF, Lathi M, Kan WL, Hercus TR, Stomski F, Hughes TP, Tergaonkar V, Parker MW, Ross DM, Majeti R, Babon JJ, et al. Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis. Science Advances. 4: eaat3834. PMID 30498775 DOI: 10.1126/sciadv.aat3834  0.32
2018 Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer JP, Agoram B, ... ... Majeti R, et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. The New England Journal of Medicine. 379: 1711-1721. PMID 30380386 DOI: 10.1056/NEJMoa1807315  0.56
2018 Chan CKF, Gulati GS, Sinha R, Tompkins JV, Lopez M, Carter AC, Ransom RC, Reinisch A, Wearda T, Murphy M, Brewer RE, Koepke LS, Marecic O, Manjunath A, Seo EY, ... ... Majeti R, et al. Identification of the Human Skeletal Stem Cell. Cell. 175: 43-56.e21. PMID 30241615 DOI: 10.1016/j.cell.2018.07.029  0.56
2017 Karamitros D, Stoilova B, Aboukhalil Z, Hamey F, Reinisch A, Samitsch M, Quek L, Otto G, Repapi E, Doondeea J, Usukhbayar B, Calvo J, Taylor S, Goardon N, Six E, ... ... Majeti R, et al. Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells. Nature Immunology. PMID 29167569 DOI: 10.1038/s41590-017-0001-2  0.36
2017 McKeown MR, Corces MR, Eaton ML, Fiore C, Lee E, Lopez JT, Chen MW, Smith D, Chan SM, Koenig JL, Austgen K, Guenther MG, Orlando DA, Lovén J, Fritz CC, ... Majeti R, et al. Super-Enhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist. Cancer Discovery. PMID 28729405 DOI: 10.1158/2159-8290.CD-17-0399  0.76
2017 Sinha S, Thomas D, Chan S, Gao Y, Brunen D, Torabi D, Reinisch A, Hernandez D, Chan A, Rankin EB, Bernards R, Majeti R, Dill DL. Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data. Nature Communications. 8: 15580. PMID 28561042 DOI: 10.1038/ncomms15580  0.32
2017 Thomas D, Majeti R. Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models. Cancer Discovery. 7: 459-461. PMID 28461409 DOI: 10.1158/2159-8290.CD-17-0270  0.32
2017 Thomas D, Majeti R. Biology and relevance of human acute myeloid leukemia stem cells. Blood. PMID 28159741 DOI: 10.1182/blood-2016-10-696054  0.32
2016 Chao MP, Gentles AJ, Chatterjee S, Lan F, Reinisch A, Corces MR, Xavy S, Shen J, Haag D, Chanda S, Sinha R, Morganti RM, Nishimura T, Ameen M, Wu H, ... ... Majeti R, et al. Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease. Cell Stem Cell. PMID 28089908 DOI: 10.1016/j.stem.2016.11.018  0.56
2016 Huang M, Garcia JS, Thomas D, Zhu L, Nguyen LX, Chan SM, Majeti R, Medeiros BC, Mitchell BS. Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells. Oncotarget. PMID 27732946 DOI: 10.18632/oncotarget.12493  0.76
2016 Corces MR, Buenrostro JD, Wu B, Greenside PG, Chan SM, Koenig JL, Snyder MP, Pritchard JK, Kundaje A, Greenleaf WJ, Majeti R, Chang HY. Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nature Genetics. PMID 27526324 DOI: 10.1038/ng.3646  0.56
2016 Jonas BA, Johnson C, Gratzinger D, Majeti R. Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell Activity. Plos One. 11: e0159189. PMID 27428079 DOI: 10.1371/journal.pone.0159189  0.4
2016 Thomas D, Majeti R. Burning Fat Fuels Leukemic Stem Cell Heterogeneity. Cell Stem Cell. 19: 1-2. PMID 27392217 DOI: 10.1016/j.stem.2016.06.014  0.32
2016 Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer JP, Liu J, Lim JS, Yang D, Seitz G, Nguyen T, Wu D, Jude K, ... ... Majeti R, et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. The Journal of Clinical Investigation. PMID 27294525 DOI: 10.1172/JCI81603  0.56
2016 Reinisch A, Thomas D, Corces MR, Zhang X, Gratzinger D, Hong WJ, Schallmoser K, Strunk D, Majeti R. A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. Nature Medicine. PMID 27213817 DOI: 10.1038/nm.4103  0.48
2016 Zhu L, Li Q, Wong SH, Huang M, Klein BJ, Shen J, Ikenouye L, Onishi M, Schneidawind D, Buechele C, Hansen L, Duque-Afonso J, Zhu F, Mas Martin G, Gozani O, ... Majeti R, et al. ASH1L links histone H3 lysine 36 di-methylation to MLL leukemia. Cancer Discovery. PMID 27154821 DOI: 10.1158/2159-8290.CD-16-0058  0.56
2016 Piccione EC, Juarez S, Tseng S, Liu J, Stafford M, Narayanan C, Wang L, Weiskopf K, Majeti R. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27126995 DOI: 10.1158/1078-0432.CCR-15-2503  0.52
2015 Mazumdar C, Shen Y, Xavy S, Zhao F, Reinisch A, Li R, Corces MR, Flynn RA, Buenrostro JD, Chan SM, Thomas D, Koenig JL, Hong WJ, Chang HY, Majeti R. Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation. Cell Stem Cell. PMID 26607380 DOI: 10.1016/j.stem.2015.09.017  0.56
2015 Sykes SM, Kokkaliaris KD, Milsom MD, Levine RL, Majeti R. Clonal Evolution of Preleukemic hematopoietic stem cells in acute myeloid leukemia. Experimental Hematology. PMID 26455528 DOI: 10.1016/j.exphem.2015.08.012  0.56
2015 Jung N, Dai B, Gentles AJ, Majeti R, Feinberg AP. An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis. Nature Communications. 6: 8489. PMID 26444494 DOI: 10.1038/ncomms9489  0.56
2015 Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, Willingham S, Howard M, Prohaska S, Volkmer J, Chao M, Weissman IL, Majeti R. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential. Plos One. 10: e0137345. PMID 26390038 DOI: 10.1371/journal.pone.0137345  0.56
2015 Reinisch A, Chan SM, Thomas D, Majeti R. Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells. Seminars in Hematology. 52: 150-64. PMID 26111462 DOI: 10.1053/j.seminhematol.2015.03.008  0.76
2015 Piccione EC, Juarez S, Liu J, Tseng S, Ryan C, Narayanan C, Wang L, Weiskopf K, Majeti R. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. Mabs. 0. PMID 26083076 DOI: 10.1080/19420862.2015.1062192  0.56
2015 Majeti R, Dove C, McClellan JS. Reply to Fišer et al.: Myeloid reprogramming of Ph+ B-ALL: A potential therapeutic strategy. Proceedings of the National Academy of Sciences of the United States of America. 112: E3456. PMID 26069209 DOI: 10.1073/pnas.1509027112  0.56
2015 McClellan JS, Dove C, Gentles AJ, Ryan CE, Majeti R. Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages. Proceedings of the National Academy of Sciences of the United States of America. 112: 4074-9. PMID 25775523 DOI: 10.1073/pnas.1413383112  0.56
2015 Moraga I, Wernig G, Wilmes S, Gryshkova V, Richter CP, Hong WJ, Sinha R, Guo F, Fabionar H, Wehrman TS, Krutzik P, Demharter S, Plo I, Weissman IL, Minary P, ... Majeti R, et al. Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands. Cell. 160: 1196-208. PMID 25728669 DOI: 10.1016/j.cell.2015.02.011  0.56
2015 Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, Zhao F, Medeiros BC, Tyvoll DA, Majeti R. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nature Medicine. 21: 178-84. PMID 25599133 DOI: 10.1038/nm.3788  0.56
2015 Reinisch A, Etchart N, Thomas D, Hofmann NA, Fruehwirth M, Sinha S, Chan CK, Senarath-Yapa K, Seo EY, Wearda T, Hartwig UF, Beham-Schmid C, Trajanoski S, Lin Q, Wagner W, ... ... Majeti R, et al. Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. Blood. 125: 249-60. PMID 25406351 DOI: 10.1182/blood-2014-04-572255  0.56
2015 Sinha S, Thomas D, Yu L, Gentles AJ, Jung N, Corces-Zimmerman MR, Chan SM, Reinisch A, Feinberg AP, Dill DL, Majeti R. Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition. Blood. 125: 316-26. PMID 25398938 DOI: 10.1182/blood-2014-03-566018  0.56
2015 Chao MP, Hong J, Kunder C, Lester L, Schrier SL, Majeti R. Refractory warm IgM-mediated autoimmune hemolytic anemia associated with Churg-Strauss syndrome responsive to eculizumab and rituximab. American Journal of Hematology. 90: 78-81. PMID 24942207 DOI: 10.1002/ajh.23791  0.56
2014 Corces-Zimmerman MR, Majeti R. Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis. Leukemia. 28: 2276-82. PMID 25005245 DOI: 10.1038/leu.2014.211  0.48
2014 Green MR, Vicente-Dueñas C, Romero-Camarero I, Long Liu C, Dai B, González-Herrero I, García-Ramírez I, Alonso-Escudero E, Iqbal J, Chan WC, Campos-Sanchez E, Orfao A, Pintado B, Flores T, Blanco O, ... ... Majeti R, et al. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nature Communications. 5: 3904. PMID 24887457 DOI: 10.1038/ncomms4904  0.56
2014 Nguyen le XT, Chan SM, Ngo TD, Raval A, Kim KK, Majeti R, Mitchell BS. Interaction of TIF-90 and filamin A in the regulation of rRNA synthesis in leukemic cells. Blood. 124: 579-89. PMID 24850755 DOI: 10.1182/blood-2013-12-544726  0.76
2014 Lee JY, Hong WJ, Majeti R, Stearns T. Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasms. Plos One. 9: e92641. PMID 24658090 DOI: 10.1371/journal.pone.0092641  0.56
2014 Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proceedings of the National Academy of Sciences of the United States of America. 111: 2548-53. PMID 24550281 DOI: 10.1073/pnas.1324297111  0.56
2013 Chan SM, Majeti R. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. International Journal of Hematology. 98: 648-57. PMID 23949914 DOI: 10.1007/s12185-013-1407-8  0.76
2013 Huang M, Thomas D, Li MX, Feng W, Chan SM, Majeti R, Mitchell BS. Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib. Leukemia. 27: 1970-80. PMID 23877794 DOI: 10.1038/leu.2013.222  0.76
2013 McClellan JS, Majeti R. The cancer stem cell model: B cell acute lymphoblastic leukaemia breaks the mould. Embo Molecular Medicine. 5: 7-9. PMID 23229878 DOI: 10.1002/emmm.201202207  0.56
2013 Craddock C, Quek L, Goardon N, Freeman S, Siddique S, Raghavan M, Aztberger A, Schuh A, Grimwade D, Ivey A, Virgo P, Hills R, McSkeane T, Arrazi J, Knapper S, ... ... Majeti R, et al. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia. 27: 1028-36. PMID 23223186 DOI: 10.1038/leu.2012.312  0.56
2013 Jan M, Majeti R. Clonal evolution of acute leukemia genomes. Oncogene. 32: 135-40. PMID 22349821 DOI: 10.1038/onc.2012.48  0.48
2012 Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR, Majeti R. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Science Translational Medicine. 4: 149ra118. PMID 22932223 DOI: 10.1126/scitranslmed.3004315  0.56
2012 Ochsenreither S, Majeti R, Schmitt T, Stirewalt D, Keilholz U, Loeb KR, Wood B, Choi YE, Bleakley M, Warren EH, Hudecek M, Akatsuka Y, Weissman IL, Greenberg PD. Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood. 119: 5492-501. PMID 22529286 DOI: 10.1182/blood-2011-07-365890  0.56
2012 Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, Contreras-Trujillo H, Liu J, Majeti R, West RB, Fletcher JA, Beck AH, Weissman IL, van de Rijn M. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proceedings of the National Academy of Sciences of the United States of America. 109: 6656-61. PMID 22451919 DOI: 10.1073/pnas.1121629109  0.56
2012 Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, ... ... Majeti R, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proceedings of the National Academy of Sciences of the United States of America. 109: 6662-7. PMID 22451913 DOI: 10.1073/pnas.1121623109  0.56
2012 Chao MP, Weissman IL, Majeti R. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Current Opinion in Immunology. 24: 225-32. PMID 22310103 DOI: 10.1016/j.coi.2012.01.010  0.56
2012 Chao MP, Majeti R, Weissman IL. Programmed cell removal: a new obstacle in the road to developing cancer. Nature Reviews. Cancer. 12: 58-67. PMID 22158022 DOI: 10.1038/nrc3171  0.56
2012 McClellan JS, Kohrt HE, Coutre S, Gotlib JR, Majeti R, Alizadeh AA, Medeiros BC. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica. 97: 133-6. PMID 21993679 DOI: 10.3324/haematol.2011.046490  0.56
2012 Chao MP, Majeti R, Weissman I. Response: Mechanisms of targeting CD47-SIRPα in hematologic malignancies Blood. 119: 4334-4335. DOI: 10.1182/blood-2012-02-411249  0.56
2011 Alizadeh AA, Majeti R. Surprise! HSC are aberrant in chronic lymphocytic leukemia. Cancer Cell. 20: 135-6. PMID 21840478 DOI: 10.1016/j.ccr.2011.08.001  0.56
2011 Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, Weissman IL. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood. 118: 4890-901. PMID 21828138 DOI: 10.1182/blood-2011-02-338020  0.56
2011 Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL, Majeti R. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proceedings of the National Academy of Sciences of the United States of America. 108: 5009-14. PMID 21383193 DOI: 10.1073/pnas.1100551108  0.56
2011 Gibbs KD, Gilbert PM, Sachs K, Zhao F, Blau HM, Weissman IL, Nolan GP, Majeti R. Single-cell phospho-specific flow cytometric analysis demonstrates biochemical and functional heterogeneity in human hematopoietic stem and progenitor compartments. Blood. 117: 4226-33. PMID 21357764 DOI: 10.1182/blood-2010-07-298232  0.56
2011 Majeti R, Weissman IL. Human acute myelogenous leukemia stem cells revisited: there's more than meets the eye. Cancer Cell. 19: 9-10. PMID 21251611 DOI: 10.1016/j.ccr.2011.01.007  0.56
2011 Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL, Majeti R. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Research. 71: 1374-84. PMID 21177380 DOI: 10.1158/0008-5472.CAN-10-2238  0.56
2011 Gentles AJ, Majeti R, Alizadeh AA. Leukemic stem cell gene expression signature and clinical outcomes in acute myeloid leukemia: Reply Jama - Journal of the American Medical Association. 305: 1094-1095. DOI: 10.1001/jama.2011.300  0.56
2010 Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, Majeti R, Weissman IL. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Science Translational Medicine. 2: 63ra94. PMID 21178137 DOI: 10.1126/scitranslmed.3001375  0.56
2010 Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. Jama. 304: 2706-15. PMID 21177505 DOI: 10.1001/jama.2010.1862  0.56
2010 Kohrt HE, Patel S, Ho M, Owen T, Pollyea DA, Majeti R, Gotlib J, Coutre S, Liedtke M, Berube C, Alizadeh AA, Medeiros BC. Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience. American Journal of Hematology. 85: 877-81. PMID 20872554 DOI: 10.1002/ajh.21857  0.56
2010 Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, ... ... Majeti R, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 142: 699-713. PMID 20813259 DOI: 10.1016/j.cell.2010.07.044  0.56
2010 Diehn M, Majeti R. Metastatic cancer stem cells: an opportunity for improving cancer treatment? Cell Stem Cell. 6: 502-3. PMID 20569685 DOI: 10.1016/j.stem.2010.05.001  0.56
2010 Jaiswal S, Chao MP, Majeti R, Weissman IL. Macrophages as mediators of tumor immunosurveillance. Trends in Immunology. 31: 212-9. PMID 20452821 DOI: 10.1016/j.it.2010.04.001  0.56
2010 Medeiros BC, Kohrt HE, Arber DA, Bangs CD, Cherry AM, Majeti R, Kogel KE, Azar CA, Patel S, Alizadeh AA. Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). Leukemia Research. 34: 594-7. PMID 19781775 DOI: 10.1016/j.leukres.2009.08.029  0.56
2009 Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, van Rooijen N, Weissman IL. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 138: 286-99. PMID 19632179 DOI: 10.1016/j.cell.2009.05.045  0.56
2009 Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 138: 271-85. PMID 19632178 DOI: 10.1016/j.cell.2009.05.046  0.56
2009 Majeti R, Becker MW, Tian Q, Lee TL, Yan X, Liu R, Chiang JH, Hood L, Clarke MF, Weissman IL. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proceedings of the National Academy of Sciences of the United States of America. 106: 3396-401. PMID 19218430 DOI: 10.1073/pnas.0900089106  0.56
2009 Ooi AG, Karsunky H, Majeti R, Butz S, Vestweber D, Ishida T, Quertermous T, Weissman IL, Forsberg EC. The adhesion molecule esam1 is a novel hematopoietic stem cell marker. Stem Cells (Dayton, Ohio). 27: 653-61. PMID 19074415 DOI: 10.1634/stemcells.2008-0824  0.56
2008 Park CY, Majeti R, Weissman IL. In vivo evaluation of human hematopoiesis through xenotransplantation of purified hematopoietic stem cells from umbilical cord blood. Nature Protocols. 3: 1932-40. PMID 19180077 DOI: 10.1038/nprot.2008.194  0.56
2007 Majeti R, Park CY, Weissman IL. Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell. 1: 635-45. PMID 18371405 DOI: 10.1016/j.stem.2007.10.001  0.56
2005 Hermiston ML, Tan AL, Gupta VA, Majeti R, Weiss A. The juxtamembrane wedge negatively regulates CD45 function in B cells. Immunity. 23: 635-47. PMID 16356861 DOI: 10.1016/j.immuni.2005.11.001  0.92
2002 Hermiston ML, Xu Z, Majeti R, Weiss A. Reciprocal regulation of lymphocyte activation by tyrosine kinases and phosphatases. The Journal of Clinical Investigation. 109: 9-14. PMID 11781344 DOI: 10.1172/JCI14794  0.92
2001 Majeti R, Weiss A. Regulatory mechanisms for receptor protein tyrosine phosphatases. Chemical Reviews. 101: 2441-8. PMID 11749382 DOI: 10.1021/cr000085m  0.92
2001 Baker JE, Majeti R, Tangye SG, Weiss A. Protein tyrosine phosphatase CD148-mediated inhibition of T-cell receptor signal transduction is associated with reduced LAT and phospholipase Cgamma1 phosphorylation. Molecular and Cellular Biology. 21: 2393-403. PMID 11259588 DOI: 10.1128/MCB.21.7.2393-2403.2001  0.92
2000 Majeti R, Xu Z, Parslow TG, Olson JL, Daikh DI, Killeen N, Weiss A. An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity. Cell. 103: 1059-70. PMID 11163182 DOI: 10.1016/S0092-8674(00)00209-9  0.56
1999 Lagunoff M, Majeti R, Weiss A, Ganem D. Deregulated signal transduction by the K1 gene product of Kaposi's sarcoma-associated herpesvirus. Proceedings of the National Academy of Sciences of the United States of America. 96: 5704-9. PMID 10318948 DOI: 10.1073/pnas.96.10.5704  0.56
1998 Majeti R, Bilwes AM, Noel JP, Hunter T, Weiss A. Dimerization-induced inhibition of receptor protein tyrosine phosphatase function through an inhibitory wedge. Science (New York, N.Y.). 279: 88-91. PMID 9417031 DOI: 10.1126/science.279.5347.88  0.92
1998 Noel JP, Bilwcs A, Majeti R, Weiss A, Unter T. Receptor protein-tyrosine phosphatase alpha signalling Faseb Journal. 12: A1327.  0.92
1998 Majeti R, Bilwes AM, Noel JP, Hunter T, Weiss A. Ligand-induced dimerization regulates receptor protein tyrosine phosphatase function via an inhibitory wedge Faseb Journal. 12: A937.  0.92
Show low-probability matches.